PharmaCielo Ltd.
PCLOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $3 | $2 | $5 | $2 |
| % Growth | 125.7% | -71% | 172.9% | – |
| Cost of Goods Sold | $3 | $3 | $5 | $6 |
| Gross Profit | $1 | -$1 | $1 | -$4 |
| % Margin | 21% | -88.8% | 12.8% | -221.5% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $5 | $8 | $11 | $18 |
| SG&A Expenses | $5 | $8 | $12 | $19 |
| Sales & Mktg Exp. | -$0 | $0 | $1 | $1 |
| Other Operating Expenses | $0 | $0 | $0 | $2 |
| Operating Expenses | $6 | $8 | $12 | $21 |
| Operating Income | -$5 | -$10 | -$11 | -$25 |
| % Margin | -140.9% | -629.2% | -215.4% | -1,295.3% |
| Other Income/Exp. Net | -$4 | -$7 | -$3 | -$1 |
| Pre-Tax Income | -$9 | -$16 | -$15 | -$27 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$16 | -$15 | -$27 |
| % Margin | -262.7% | -1,057.1% | -273.5% | -1,369.1% |
| EPS | -0.052 | -0.1 | -0.096 | -0.18 |
| % Growth | 47.8% | -4.1% | 46.6% | – |
| EPS Diluted | -0.052 | -0.1 | -0.096 | -0.18 |
| Weighted Avg Shares Out | 175 | 160 | 151 | 146 |
| Weighted Avg Shares Out Dil | 175 | 160 | 151 | 146 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | -$0 | $0 |
| Interest Expense | $3 | $3 | $2 | $1 |
| Depreciation & Amortization | $1 | $1 | $2 | $1 |
| EBITDA | -$5 | -$12 | -$11 | -$25 |
| % Margin | -132.3% | -790.6% | -197.8% | -1,277.1% |